Last reviewed · How we verify
Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)
Shuxuening injection is a multi-target neuroprotective agent, it is expected to play a neuroprotective role on the basis of intravenous thrombolysis therapy. The primary purpose of this multicenter, randomized, double-blind, placebo-parallel controlled trial is to evaluate the efficacy and safety of Shuxuening injection in the treatment with intravenous thrombolysis in patients with ischemic stroke.
Details
| Lead sponsor | Beijing Tiantan Hospital |
|---|---|
| Phase | PHASE3 |
| Status | RECRUITING |
| Enrolment | 1380 |
| Start date | Thu Jan 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jul 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Ischemic Stroke, Acute
Interventions
- Shuxuening Injection
- Placebo
Countries
China